A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

NCT ID: NCT05248841

Last Updated: 2022-09-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 104 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-08
• Study Completion Date: 2022-08-31

Brief Summary

This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.

Detailed Description

This will be a double-blind, single-dose, randomized, two-period, two-treatment, two-sequence crossover clamp study performed at a single study center. The study population consists of healthy adult male subjects.

The study will comprise of:

• A screening period: maximum 28 days prior to first dose administration.
• Admission: Subjects will be admitted to the study center on Day -1
• Two Treatment Periods (Treatment Periods 1 and 2): Subjects will be randomized to either of the 2 treatment sequences (AB or BA) on Day 1 of Treatment Period 1 to receive either test or reference product as per randomization schedule in a 1:1 ratio.

• Treatment A (Test Formulation): HEC-Glargine
• Treatment B (Reference Formulation): US-Lantus®

On Day 1 of each Treatment Period, the study drug or reference product will be administered as a single morning dose to subjects in a fasting state. There will be a wash-out period of at least 7 calendar days. Each subject will receive both test and reference products in a crossover pattern over Treatment Periods 1 and 2.

Conditions

Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

HEC-Glargine Treatment A (Test)

Subjects will receive single doses of Test Formulation HEC-Glargine on Day 1 of Treatment periods 1 and 2 followed by at least 7-21 days washout.

Group Type: EXPERIMENTAL

HEC-Glargine

Intervention Type: DRUG

Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.

US-Lantus Treatment B (Reference)

Subjects will receive single doses of Reference Formulation Lantus on Day 1 followed of Treatment periods 1 and 2 by at least 7-21 days washout.

Group Type: ACTIVE_COMPARATOR

US-Lantus

Intervention Type: DRUG

Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.

Interventions

HEC-Glargine

Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.

Intervention Type: DRUG

US-Lantus

Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.

Intervention Type: DRUG

Other Intervention Names

Insulin glargine

Eligibility Criteria

Inclusion Criteria

• Participant has body weight not less than 60 kg and body mass index between 18.5 and 30.0 kg/m^2 (both inclusive).
• Glycohemoglobin (HbA1c) levels are <6.0%.
• Normal oral glucose tolerance test conducted within the previous 6 months
• Medical history, vital signs, physical examination, standard 12-lead electrocardiogram (ECG) and laboratory investigations should be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests
• Non-smokers or mild to moderate smokers (≤ 10 cigarettes or pipes per day).

Exclusion Criteria

• Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
• Current alcohol use >21 units of alcohol per week
• Regular exposure to substances of abuse (other than alcohol) within the past year.
• Use of any medication, prescribed or over-the-counter or herbal remedies
• Participation in another study with an experimental drug, where the last administration of the previous study drug was within 12 weeks before administration of study drug in this study.
• Treatment within the previous 3 months before the first administration of study drug with any drug with a well-defined potential for adversely affecting a major organ or system.
• A major disease (i.e., a disease that could not be treated at home, but the subject had to be hospitalized or needed general anesthesia usually for a major operation) during the 3 months before commencement of the screening period.
• Positive test for insulin antibodies.
• History of bronchial asthma or any other bronchospastic disease, and/or convulsions, and/or porphyria.
• Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
• Resting pulse of >100 beats per minute (bpm) or <40 bpm during the screening period, either supine or standing.
• Hypertension diagnosed during screening or current diagnosis of hypertension.
• Hemoglobin count deviating more than 10% of the lower limit of normal.
• Clinically relevant abnormalities in the coagulation status.
• History of bleeding disorders.
• Veins unsuitable for venous blood collection and cannulation.
• Any specific study drug safety concern.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Parexel

INDUSTRY

Sponsor Role: collaborator

FARMOVS (Pty) Ltd

UNKNOWN

Sponsor Role: collaborator

Lannett Company, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

FARMOVS Clinical Research Organization

Bloemfontein, Free State, South Africa

Countries

South Africa

Other Identifiers

PIND147873

Identifier Type: OTHER

Identifier Source: secondary_id

LC-INS-2001

Identifier Type: -

Identifier Source: org_study_id